Metropolitan Life Insurance Co. NY continued to hold its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) during the first quarter, Holdings Channel reports. The fund owned 42,512 shares of the medical instruments supplier’s stock at the end of the first quarter. Metropolitan Life Insurance Co. NY’s holdings in OraSure Technologies were worth $550,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Victory Capital Management Inc. purchased a new position in shares of OraSure Technologies during the first quarter worth about $100,000. Profund Advisors LLC purchased a new position in shares of OraSure Technologies during the first quarter worth about $137,000. BNP Paribas Arbitrage SA increased its position in shares of OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock worth $139,000 after buying an additional 9,723 shares during the last quarter. Private Advisor Group LLC increased its position in shares of OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock worth $135,000 after buying an additional 723 shares during the last quarter. Finally, Capital Fund Management S.A. purchased a new position in shares of OraSure Technologies during the first quarter worth about $144,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Shares of OraSure Technologies, Inc. (NASDAQ OSUR) traded down 1.982% during mid-day trading on Thursday, reaching $20.525. 238,727 shares of the company’s stock traded hands. The firm’s 50-day moving average is $18.17 and its 200 day moving average is $13.95. OraSure Technologies, Inc. has a one year low of $6.84 and a one year high of $21.59. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 37.939 and a beta of 1.57.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.02. The business had revenue of $40.18 million for the quarter, compared to analyst estimates of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The company’s revenue for the quarter was up 28.1% compared to the same quarter last year. During the same period last year, the firm posted $0.07 earnings per share. Analysts predict that OraSure Technologies, Inc. will post $0.48 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Continues to Hold Stake in OraSure Technologies, Inc. (OSUR)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/10/metropolitan-life-insurance-co-ny-continues-to-hold-stake-in-orasure-technologies-inc-osur.html.

A number of research analysts have recently issued reports on the stock. BidaskClub downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Canaccord Genuity lifted their price objective on shares of OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Jefferies Group LLC lifted their price objective on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Stephens reaffirmed an “overweight” rating and issued a $19.00 price objective (up previously from $14.00) on shares of OraSure Technologies in a research report on Tuesday, July 11th. Finally, Zacks Investment Research downgraded shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, April 12th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. OraSure Technologies presently has an average rating of “Buy” and an average price target of $15.46.

In other news, Director Ronny B. Lancaster sold 89,684 shares of the firm’s stock in a transaction that occurred on Tuesday, May 30th. The shares were sold at an average price of $14.79, for a total transaction of $1,326,426.36. Following the transaction, the director now directly owns 6,295 shares in the company, valued at $93,103.05. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Ronald H. Spair sold 510,112 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $20.66, for a total transaction of $10,538,913.92. Following the transaction, the chief financial officer now owns 208,606 shares in the company, valued at $4,309,799.96. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,036,670 shares of company stock worth $19,807,152. Insiders own 7.80% of the company’s stock.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.